Truist Securities Reiterates Buy Rating#
Truist Securities has reaffirmed a Buy rating for Ascentage Pharma Group (NASDAQ:AAPG) and set a price target of $51.00. Currently, the stock is trading at $23.59, having decreased by 18% over the past week and 37% over the last six months. Despite this decline, analysts maintain a Strong Buy consensus, with price targets ranging from $45 to $55.
Pipeline Developments#
Recently, Truist hosted CFO Veet Misra in San Francisco, where they discussed several key developments expected through 2027. Notable upcoming data includes olverem for chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), as well as lisa for high-risk myelodysplastic syndromes (HR MDS), all set for the first half of 2027. Truist believes olverem could become a preferred second-line treatment in CML, while lisa's unique development path faces less competition.
Future Growth Potential#
Truist also pointed out the potential of a next-generation asset, a BTK degrader, with initial data anticipated in late 2026 or early 2027. They expressed optimism about Ascentage's growth story, noting a series of upcoming catalysts and reduced risks associated with operations in China. This positioning could lead to a broader global valuation for the company.
Revenue Growth and Analyst Optimism#
In recent news, Ascentage Pharma reported a significant revenue increase for 2025, reaching $82.1 million, which represents a 90% year-over-year growth. This surge is largely attributed to the sales of Olverembatinib and the launch of Lisaftoclax, marking the first time two commercial products have contributed to the company’s revenue. Analysts from Deutsche Bank and BTIG have initiated coverage with buy ratings, emphasizing the potential of these treatments. Oppenheimer also maintained an Outperform rating, highlighting the company’s growth prospects in China. This collective optimism among analysts underscores a positive outlook for Ascentage Pharma's future.